News | June 16, 2014

New Data Presented on Neuraceq Amyloid Plaque Imaging Agent at SNMMI 2014

New Data Presented on Neuraceq Amyloid Plaque Imaging Agent at SNMMI 2014

June 16, 2014 — Piramal Imaging released details from research presented at the 2014 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in St. Louis. Research findings relating to the development and approval of Neuraceq (florbetaben F18 injection) were presented during the AD II: Advanced Approaches Session.

“The strength of our partnership with the research community has been on display throughout SNMMI,” said Andrew Stephens, M.D., chief medical officer, Piramal Imaging. “It is this partnership that allows us to push the innovation envelope for Piramal and molecular imaging as a field. The research presented here will be the basis for product advancements for years to come.”

At SNMMI there was a specific focus on science that improved the understanding of the value of beta-amyloid imaging as a tool for assessing patients with cognitive impairment. As independent researchers, these clinical experts discussed uses of beta-amyloid agents that are not completely reflected in the label approved by the U.S. Food and Drug Administration (FDA). Nevertheless, they highlight the emerging science underlying this new diagnostic tool. The three presentations highlighted below, each led by different key researchers, offered new insight into the clinical value and application for Neuraceq:

  • In a presentation titled “A negative florbetaben PET scan reliably excludes AD pathology as confirmed by histopathology,” John Seibyl, M.D., CEO of Molecular NeuroImaging and clinical professor of neurology at Yale University, focused on the very high negative predictive value of Neuraceq scans.
  • In his presentation “Efficacy and reliability of the visual assessment of 18F-florbetaben PET scans in the detection of beta-amyloid neuritic plaques in the brain,” Osama Sabri, M.D., Ph.D., University of Leipzig, Germany, revealed that the robustness of the visual scan assessment method developed for Neuraceq results in high sensitivity and specificity, even in challenging scans and restrictive reading conditions.
  • Henryk Barthel, M.D., Ph.D., University of Leipzig, Germany, presented “Early ß-amyloid PET images are a valuable surrogate biomarker of neuronal injury in dementia patients,” which showed that a single tracer injection may provide information on both neuronal integrity (as FDG) and beta-amyloid deposition.

Neuraceq was approved in the United States and European Union earlier this year. It is indicated for positron emission tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive decline.

For more information:

Related Content

Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.
The Siemens Biograph Vision PET-CT system was released in mid-2018.

The Siemens Biograph Vision PET-CT system was released in mid-2018.

Feature | Nuclear Imaging | September 07, 2018 | By Dave Fornell
Nuclear imaging technology for both single photon emission computed tomography (SPECT) and positron emission tomography...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Brain Iron Levels May Predict Multiple Sclerosis Disabilities
News | Neuro Imaging | August 31, 2018
A new, highly accurate magnetic resonance imaging (MRI) technique can monitor iron levels in the brains of multiple...
Study Finds Multiple Sclerosis Drug Slows Brain Shrinkage

An NIH-funded clinical trial suggested that the anti-inflammatory drug ibudilast may slow brain shrinkage caused by progressive MS. Image courtesy of Robert J. Fox, M.D., Cleveland Clinic.

News | Neuro Imaging | August 30, 2018
August 30, 2018 — Results from a clinical...
iSchemaView RAPID Technology Now Installed in More Than 500 Stroke Centers
News | Neuro Imaging | August 27, 2018
iSchemaView announced that more than 575 stroke centers in 22 countries have selected the RAPID advanced imaging...
Brain Study of 62,454 Scans Identifies Drives of Brain Aging
News | SPECT Imaging | August 27, 2018
In the largest known brain imaging study, scientists from five institutions evaluated 62,454 brain single photon...
Abnormal Protein Concentrations Found in Brains of Military Personnel With Suspected CTE

Researchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encephalopathy in living patients. In this image, warmer colors indicate a higher concentration of the tracer, which binds to abnormal proteins in the brain. Credit UCLA Health.

News | PET Imaging | August 24, 2018
August 24, 2018 — In a small study of
Radiation Therapy Affects Event Recall for Children With Brain Tumors
News | Radiation Therapy | August 24, 2018
Children with certain types of brain tumors who undergo radiation treatment are less likely to recall the specifics of...